Why You Don't Need to Cycle CJC-1295 or Tesamorelin

The standard advice is to cycle CJC-1295 and Ipamorelin on a three months on, one month off schedule, and most people follow it without question because the two compounds come pre-mixed in the same vial. The problem is that this protocol is built around one of those compounds, not both, and treating them as a single system causes a lot of confusion about what actually needs to happen and why.

To understand this properly, you need a map of the whole chain first.

Your body releases growth hormone through a two-signal system. The first signal is something called GHRH, or growth hormone releasing hormone, which is the primary driver that tells your pituitary to produce and release growth hormone. The second signal comes through a completely separate receptor called the ghrelin receptor, sometimes referred to as the GHS-R, and this one amplifies the GHRH signal and adds its own pulse of growth hormone release on top of it. These two receptor systems sit on the same pituitary cells but operate independently, and they respond very differently to chronic stimulation.

Ipamorelin works through the ghrelin receptor, and this is where the desensitization problem actually lives.

When you stimulate the ghrelin receptor continuously, your body initiates a process called beta-arrestin mediated internalization, which is essentially the cell pulling its own receptors off the surface and storing them inside the cell where they cannot respond to incoming signals. The cell is not malfunctioning. It is doing exactly what it is supposed to do when it detects a receptor that has been over-activated, and it is reducing its sensitivity to prevent overstimulation. The practical result is that the longer you run Ipamorelin without a break, the fewer functional ghrelin receptors you have available, and your growth hormone output per dose keeps declining.

A 16-week human trial quantified exactly how severe this is. By week 16 of continuous ghrelin receptor stimulation, GH response had dropped approximately 45 percent from where it started. That is not a marginal effect. And when subjects stopped for four weeks, response returned to baseline, meaning the receptors came back to the surface and sensitivity restored. This is the evidence behind the three months on, one month off structure, and it is real and well-supported.

But here is where the protocol breaks down as universal advice.

CJC-1295 and tesamorelin work through the GHRH receptor, which is an entirely separate system. A study using perifused rat pituitary cells directly tested whether stimulating one receptor system would cause desensitization in the other, and it found no cross-desensitization at all. The two systems are independent enough that you can exhaust one without affecting the other in either direction. So the question becomes: does the GHRH receptor desensitize on its own when you stimulate it continuously?

The tesamorelin data answers this as directly as you could ask for.

Tesamorelin is a stabilized analog of GHRH, meaning it binds the same receptor that natural GHRH binds. In the Phase 3 clinical trials that led to FDA approval, patients received daily tesamorelin injections for 52 weeks and IGF-1 levels, which are the best marker of sustained growth hormone activity, held steady the entire time with no decline. The 26-week data from a separate trial in HIV patients showed the same thing, sustained IGF-1 elevation with no attenuation of response across the full study period.

The reason the GHRH receptor does not desensitize the way the ghrelin receptor does comes down to timing.

Tesamorelin has a half-life of roughly 26 to 38 minutes. You inject it once, it binds the receptor, triggers a growth hormone pulse, and then it is cleared from the system. The GHRH receptor then has somewhere between 23 and 24 hours before the next dose arrives. That recovery window appears to be sufficient to prevent the internalization process from taking hold, because the receptor is not in a state of chronic continuous activation. It gets a brief signal and a long rest.

The ghrelin receptor under standard Ipamorelin dosing does not get that same recovery window, because Ipamorelin is typically dosed two or three times per day and the cumulative stimulation across the day keeps the receptor in an activated state long enough to trigger the internalization response.

There is also longer-term data from MK-677, which is an oral ghrelin mimetic that works through the same receptor as Ipamorelin. In a two-year continuous use study, GH and IGF-1 remained elevated throughout, which seems to contradict the desensitization story, but the distinction there is likely dose and pattern of stimulation rather than a fundamental difference in receptor behavior. The internalization process is dose and duration dependent, and the conditions in that study may not have pushed the receptor hard enough to trigger meaningful desensitization.

So if you are running CJC-1295 or tesamorelin alongside Ipamorelin in a combined protocol, you are cycling for the Ipamorelin, and that is the right call. The ghrelin receptor needs the rest, and the 45 percent response decline at 16 weeks is a concrete number that justifies the structure. But the CJC or tesamorelin component does not require that break based on anything in the published literature, and if you are running tesamorelin alone without a ghrelin receptor agonist, there is no data indicating that cycling it provides any benefit.

The deeper principle here is one that comes up across most of peptide pharmacology. Receptor desensitization is not a property of growth hormone stimulation generally. It is a property of specific receptor systems under specific stimulation conditions, and lumping compounds together because they produce a similar endpoint, more growth hormone, while ignoring how differently they arrive at that endpoint is how you end up cycling something that does not need to be cycled, or not cycling something that does.

The vial they came in together was never the reason to treat them the same way.

---

References

1. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
2. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
3. FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
4. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
5. Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness